Forced degradation studies of rapamycin: Identification of autoxidation products

Journal of Pharmaceutical and Biomedical Analysis

Volumn 59, Issue 1, 2012, Pages 194-200

  Oyler, Alan R ^a   Segmuller, Brigitte E ^b,d   Sun, Yanqiu ^a,e   Polshyna, Ann ^a,f   Dunphy, Richard ^b,g   Armstrong, Barbara L ^c   Achord, Patrick ^a,h   Maryanoff, Cynthia A ^c   Alquier, Lori ^c   Il'ichev, Yuri V ^c  

^a UNIVERSITY OF MINNESOTA DULUTH   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Cordis Corporation ^*  (United States)

^d Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^e RICE UNIVERSITY   (United States)

^f UNIVERSITY OF WISCONSIN SUPERIOR   (United States)

^g ABC Laboratories Incorporated   (United States)

^h NONE   (United States)

Author keywords

Autoxidation; Epoxides; Isomerization; NP HPLC; Sirolimus

Indexed keywords

ALCOHOL; ALKENE; EPOXIDE; FREE RADICAL; KETONE; MONOMER; OLIGOMER; RAPAMYCIN;

ARTICLE; AUTOOXIDATION; DRUG DEGRADATION; EPIMER; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 82255186624     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.10.017     Document Type: Article

References (25)

1. Pharmaceutical Stress Testing, Predicting Drug Degradation, Drugs and the Pharmaceutical Sciences 2005, vol. 153. Taylor & Francis, New York.
2. Hovorka S.W., Schoneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J. Pharm. Sci. 2001, 90:253-269.
3. Nelson E.D., Harmon P.A., Szymanik R.C., Teresk M.G., Li L., Seburg R.A., Reed R.A. Evaluation of solution oxygenation requirements for azonitrile-based oxidative forced degradation studies of pharmaceutical compounds. J. Pharm. Sci. 2006, 95:1527-1539.
4. Reid D.L., Calvitt C.J., Zell M.T., Miller K.G., Kingsmill C.A. Early prediction of pharmaceutical oxidation pathways by computational chemistry and forced degradation. Pharm. Res. 2004, 21:1708-1717.
5. G. Boccardi, Oxidative Susceptibility Testing, in: Ref. [1], pp. 205-234.
6. Oyler A.R., Armstrong B.L., Dunphy R., Alquier L., Maryanoff C.A., Cohen J.H., Merciadez M., Khublall A., Mehta R., Patel A., Il'ichev Yu.V. Mass balance in rapamycin autoxidation. J. Pharm. Biomed. Anal. 2008, 48:1368-1374.
7. T. Zhu, 1-Oxorapamycins, United States Patent No. US 6,399,625 B1 (WO 02/26746 A2), (June 4, 2002) (Chem. Abstr. 136 (2002) 294672).
8. Pagano T.G. Spectral assignments and reference data. Complete assignments of the 1H and 13C resonances of 40-epi-(N1-tetrazolyl)-rapamycin and revised 13C assignments for rapamycin. Magn. Reson. Chem. 2005, 43:174-175.
9. Kessler H., Haessner R., Schuler W. Structure of rapamycin: an NMR and molecular-dynamics investigation. Helv. Chim. Acta 1993, 76:117-130.
10. Zhou C.C., Stewart K.D., Dhaon M.K. An intramolecular ionic hydrogen bond stabilizes a cis amide bond rotamer of a ring-opened rapamycin-degradation product. Magn. Reson. Chem. 2005, 43:41-46.
11. Hughes P., Musser J., Conklin M., Russo R. The isolation, synthesis and characterization of an isomeric form of rapamycin. Tetrahedron Lett. 1992, 33:4739-4742.
12. Smith A.B., Condon S.M, McCauley J.A., Leazer J.L., Leahy J.W., Maleczka R.E. A unified total synthesis of the immunomodulators (-)-rapamycin and (-)-27-demethoxyrapamycin: assembly of the common C(1-20) perimeter and final elaboration. J. Am. Chem. Soc. 1997, 119:962-973.
13. Luengo J.I., Konialian-Beck A., Rozamus L.W., Holt D.A. Manipulation of the rapamycin effector domain. Selective nucleophilic substitution of the C7 methoxy group. J. Org. Chem. 1994, 59:6512-6513.
14. Yang W., Digits C.A., Hatada M., Narula S., Rozamus L.W., Huestis C.M., Wong J., Dalgarno D., Holt D.A. Selective epimerization of rapamycin via a retroaldol/aldol mechanism mediated by titanium tetraisopropoxide. Org. Lett. 1999, 1:2033-2035.
15. Grinfeld A.A., Caufield C.E., Schiksnis R.A., Mattes J.F., Chan K.W. Acid catalyzed functionalization of rapamycin. Tetrahedron Lett. 1994, 35:6835-6838.
16. Luengo J.I., Konialian A.L., Holt D.A. Studies on the chemistry of rapamycin: novel 1transformations under Lewis-acid catalysis. Tetrahedron Lett. 1993, 34:991-994.
17. Wang C.P., Chan K.W., Schiksnis R.A., Scatina J., Sisenwine S.F. High performance liquid chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two rapamycin degradation products. J. Liq. Chromatogr. 1994, 17:3383-3392.
18. Yohannes D., Myers C.D., Danishefsky S.J. Degradation of rapamycin: synthesis of a rapamycinderived fragment containing the tricarbonyl and triene sectors. Tetrahedron Lett. 1993, 34:2075-2078.
19. Steffan R.J., Kearney R.M., Hu D.C., Failli A.A., Skotnicki J.S., Schiksnis R.A., Mattes J.F., Chan K.W., Caufield C.E. Base catalyzed degradations of rapamycin. Tetrahedron Lett. 1993, 34:3699-3702.
20. Il'ichev Yu.V., Alquier L., Maryanoff C.A. Degradation of rapamycin and its ring-opened isomer: role of base catalysis. ARKIVOC 2007, xii:110-131.
21. C.A. Maryanoff, K.P.L.S. Six, R.P.G. Vandecruys, Pharmaceutical dosage forms of stable amorphous rapamycin like compounds, United States Patent No. US 20060094744 A1, (May 4, 2006) (Chem. Abstr. 144 (2006) 343407).
22. Morita M., Tokita M. Hydroxy radical, hexanal, and decadienal generation by autocatalysts in autoxidation of linoleate lone and with eleostearate. Lipids 2008, 43:589-597.
23. A.A Failli, R.J. Steffan, Rapamycin pyrazoles, United States Patent No. US 5,164,399, (November 17, 1992) (Chem. Abstr. 118 (1993) 147403).
24. D.A. Holt, J.I. Luengo, L.W. Rozamus, Jr., Rapamycin derivatives, United States Patent No. US 5,661,156, (August 26, 1997) (Chem. Abstr. 121 (1994) 435191).
25. G.F. Von Burg, 42-Oxorapamycin, United States Patent No. US 5,023,263, (June 11, 1991) (Chem. Abstr. 115 (1991) 558835).